Rigel Pharmaceuticals, Inc. (RIGL)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-04) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-03) · 99.1 | 8-K (2026-01-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-04) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-05) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-06) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-04) · 99.1 | 8-K (2025-01-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-07) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-05) · 99.1 | 8-K (2024-01-08) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Balance Sheets | ||
| Statements of Operations | ||
| Balance Sheets (P) | ||
| Condensed Statements of Comprehensive Income | — |
|
| Statements of Operations (P) | ||
| Condensed Statements of Stockholdersâ Equity | — |
|
| Statements of Cash Flows | ||
| Statements of Comprehensive Income (loss) | ||
| Statements of Comprehensive Loss | ||
| Statements of Stockholders' (deficit) Equity | ||
| Condensed Statements of Stockholders' Deficit | — |
|
| Statements of Stockholders' Equity (deficit) | ||
| Statements of Stockholders' Equity (deficit) (P) | ||
| Condensed Statements of Stockholders' Deficit (P) | — |
|
| Notes | ||
| Cash, Cash Equivalents and Short-term Investments | ||
| Cash, Cash Equivalents, Restricted Cash, and Short-term Investments | — |
|
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Description of Business and Summary of Significant Accounting Policies | — |
|
| Fair Value | ||
| In-licensing and Acquisition | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Inventories | ||
| Leases | ||
| Net Income (loss) Per Share | ||
| Net Income Per Share | — |
|
| Net Loss Per Share | ||
| Organization and Summary of Significant Accounting Policies | — |
|
| Other Balance Sheet Components | ||
| Pay Vs Performance Disclosure | ||
| Restructuring Charges | — |
|
| Revenues | ||
| Segment Information | ||
| Sponsored Research and License Agreements | — |
|
| Sponsored Research and License Agreements and Government Contracts | ||
| Sponsored Research, License Agreements and Government Contracts | — |
|
| Stock-based Compensation | ||
| Stockholders' Equity | — |
|
| Subsequent Events | ||